Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
For Investors
>
Financial Reports
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Financial Reports
27-Mar-2024
Half Yearly Report and Accounts
31-Oct-2023
Quarterly Activities/Appendix 4C Cash Flow Report
31-Jul-2023
Quarterly Activities/Appendix 4C Cash Flow Report
28-Apr-2023
Quarterly Activities/Appendix 4C Cash Flow Report
28-Feb-2023
Half Yearly Report and Accounts
15-Feb-2023
Quarterly Activities/Appendix 4C Cash Flow Report
31-Jan-2023
Quarterly Activities/Appendix 4C Cash Flow Report
31-Oct-2022
Quarterly Activities/Appendix 4C Cash Flow Report
29-Jul-2022
Quarterly Activities/Appendix 4C Cash Flow Report
29-Jul-2022
Quarterly Activities/Appendix 4C Cash Flow Report
2-May-2022
Kazia Therapeutics wraps up a busy quarter presenting paxalisib data at the AACR annual meeting
29-Apr-2022
Quarterly Activities/Appendix 4C Cash Flow Report
23-Feb-2022
Kazia Half Year Accounts and Appx 4D
31-Jan-2022
Quarterly Activities/Appendix 4C Cash Flow Report
29-Oct-2021
Quarterly Activities/Appendix 4C Cash Flow Report
30-Jul-2021
Quarterly Activities/Appendix 4C Cash Flow Report
30-Apr-2021
Appendix 4C - quarterly
24-Feb-2021
Kazia half year accounts and Appx 4D
29-Jan-2021
Appendix 4C - quarterly
14-Dec-2020
Kazia receives $1.02m R&D cash rebate
30-Oct-2020
Appendix 4C - quarterly
27-Aug-2020
Kazia Annual Report to shareholders
31-Jul-2020
Appendix 4C - quarterly
20-Feb-2020
Kazia Half Year Accounts and Appx 4D
24-Dec-2019
Kazia receives $1.4m R&D cash rebate
29-Aug-2019
Kazia Annual Report to shareholders
15-Jan-2019
Kazia receives $2.2m R&D cash rebate
8-Oct-2018
Kazia Annual Report to shareholders
29-Aug-2018
Kazia Appendix 4E and financial report
21-Feb-2018
Kazia Half Year Accounts and Appx 4D
16-Oct-2017
Novogen Annual Report to shareholders
30-Aug-2017
Novogen financial report and Appendix 4E
22-Feb-2017
Novogen half year accounts and Appx 4D
19-Oct-2016
Novogen Annual Report to shareholders
17-Mar-2016
Novogen Receives R&D Tax Incentive Cash Refund of $2.8M
22-Feb-2016
Half Yearly Report and Accounts
